RESULTS	The tacrolimus/mycophenolate mofetil group compared with the tacrolimus/sirolimus group had overall better renal allograft survival ( 91 % versus 70 % , P = 0.02 ) ; 13 patients ( 35.1 % ) in the tacrolimus/sirolimus group and 8 patients ( 17.8 % ) in the tacrolimus/mycophenolate mofetil group experienced biopsy-proven acute cellular rejection ( P = 0.07 ) .\